Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hypoparathyroidism Treatment Market

Hypoparathyroidism Treatment Market Size

  • Report ID: GMI8302
  • Published Date: Feb 2024
  • Report Format: PDF

Hypoparathyroidism Treatment Market Size

Hypoparathyroidism Treatment Market was valued at USD 1.3 billion in 2023 and is estimated to register a CAGR of 6.9% from 2024 to 2032. The market has witnessed significant growth over the recent years, driven by the increasing cases of hypoparathyroid disorders, rising number of thoracic surgeries and thyroid gland disorders, and increasing cases of thyroid cancer worldwide. Additionally, advancements in diagnostic technologies are enabling more accurate and timely diagnosis of hypoparathyroidism, leading to a higher number of patients seeking treatment. Further, growing awareness among healthcare professionals and patients about the importance of early detection and treatment is driving market growth by encouraging more proactive management of hypoparathyroidism.


Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production or secretion of parathyroid hormone (PTH) by the parathyroid glands. These small glands are located in the neck, behind the thyroid gland, and play a crucial role in regulating calcium and phosphorus levels in the body. This imbalance disrupts various physiological processes in the body, affecting the muscles, nerves, and bones.


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size for hypoparathyroidism treatment was valued at USD 1.3 billion in 2023 and is estimated to account for USD 2.4 billion by 2032, driven by the increasing cases of hypo parathyroid disorders and rising number of thoracic surgeries.

The supplements segment garnered USD 888.2 million in 2023 and is set to gain traction by 2032, attributed to the well-established safety profile of supplements, and ease of availability.

North America market for hypoparathyroidism treatment is expected to grow at 6.8% rate during 2024 and 2032, driven by the presence of advanced healthcare infrastructure with access to state-of-the-art medical facilities and specialized healthcare professionals.

Ascendis Pharma A/S, Amgen Inc., BioNTech SE, Bristol-Myers Squibb Company, Entera Bio Ltd., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., SK biopharmaceuticals Co., Ltd., Sun Pharmaceutical Industries Ltd. are some of the major industry contenders.

Hypoparathyroidism Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 290
  • Countries covered: 19
  • Pages: 165
 Download Free Sample